Synagis®Pharmacy Update: RSV Season
CenCal Health would like to assist our members and providers in preparation for the upcoming RSV season. In conjunction with the Department of Health Care Services' Children's Medical Services Network, the Synagis®prophylaxis season will begin November 1, 2017, and run through March 31, 2018. Medical Request Forms (MRFs) will be accepted beginning October 1st for initial administration beginning November 1st to ensure that the infant's/child's weight is current.
Synagis®is required to be ordered through our Specialty Pharmacy vendor, Diplomat Specialty Pharmacy. Order forms can be obtained through the CenCal Health website at: www.cencalhealth.org or by contacting Diplomat Specialty Pharmacy directly at (877) 319-6337. Please contact CenCal Health Pharmacy Services Department at (805) 562-1080 if you have any questions or need any assistance.
Prepare for 2017-2018 Flu Season
The Flu Season is now upon us. The Pharmacy Flu Program can help your patients stay healthy this flu season. As part of the pharmacy benefits provided by CenCal Health and MedImpact, our members are eligible to receive the flu vaccine directly from a participating pharmacy in our network. CenCal Health members may choose from a variety of participating pharmacy locations including drugs stores, supermarkets, retailers and independent pharmacies. Members may contact their local pharmacy for vaccination hours and appointment requirements. If providers chose to administer the flu vaccine in their office, they can bill CenCal Health.
If you have any questions regarding the Pharmacy Flu Program, please contact the CenCal Health Pharmacy Services Department at (800) 421-2560 ext. 1080.
Formulary Updates September-October 2017
Formulary Updates May-June 2017
Preferred Hepatitis C Regimens
Effective October 1, 2017, CenCal Health will add and prefer Mavyret®as the treatment of choice for treatent naive Hepatitis C Genotype 1-6. Vosevi® will be added to the formulary as the treatment of choice for treatment failures. Zepatier® and Epclusa® will be removed from the formulary. CenCal Health Prior Authorization requirements, mirroring clinical policy from DHCS, have not changed and will remain in effect for the new preferred regimens. The preferred agent change will be for new starts beginning October 1st, 2017 and will not affect any member currently on a non-preferred regimen.
Inhaled Corticosteroid (ICS) Formulary Addition
CenCal Health has added an additional Inhaled Corticosteroid (ICS) option to the formulary, ArmonAir RespiClick (fluticasone proprionate) is available without restrictions.
Inhaled Corticosteroid/Long-Acting-Beta-Agonist (ICS/LABA) Formulary Addition
Effective September 1st, 2017, CenCal Health Formulary includes the authorized generic for AirDuo RespiClick, Fluticasone/Salmeterol inhaler. AirDuo RespiClick will be the preferred ICS/LABA agent for members >12 years of age with a diagnosis of asthma who have tried/failed an ICS agent.
In efforts to minimize any disruption to CenCal Health providers and members during this change, beginning November 1, 2017 providers who have members on any of the non-preferred ICS/LABA inhalers will receive a Prescription Change Form via fax requesting providers to authorize a new prescription to CenCal Health's preferred ICS/LABA inhaler. The form will serve as a valid order to begin dispensing the new medication with the next routine prescription fill.
For more information, please contact CenCal Health's Pharmacy Department at (805) 562-1080.
CenCal Health has made several changes to our Formulary based on clinical review, provider interest, cost and utilization analysis.
All of the changes represent development and growth of our current Formulary thus giving more choices to the prescribing physician. The changes are represented in summary on the chart below.
DUR: Educational Articles